KRAS and pancreatic ductal adenocarcinoma: Substrates of DHHC20 are the epidermal growth factor receptor (EGFR) in breast cancer cells41, 42, which causes increased sensitivity to EGFR inhibitors as well as YTH N6-Methyladenosine RNA Binding Protein F3 (YTHDF3) in pancreatic ductal adenocarcinoma in the context of KRAS signaling43.